At the 2025 San Antonio Breast Cancer Symposium (SABCS), Plus Therapeutics and its clinical partners shared important progress in the fight against leptomeningeal metastases (LM) with the presentation of Phase 1 dose escalation results from the ReSPECT-LM clinical trial.
Led by Dr. Andrew Brenner, the poster and oral presentation generated engagement from oncologists, researchers, and clinical investigators focused on improving outcomes for patients facing this devastating complication of metastatic cancer.
We extend our sincere thanks to everyone who visited the presentation and to the dedicated investigators and trial sites whose continued efforts are helping push this critical study forward.
What is the ReSPECT-LM Clinical Trial?
The ReSPECT-LM trial is a Phase 1 clinical study evaluating REYOBIQ™, Plus Therapeutics’ targeted radiotherapeutic approach for treating leptomeningeal metastases, a condition in which cancer spreads to the membranes surrounding the brain and spinal cord.
LM remains one of the most challenging complications of advanced cancer, particularly in patients with breast cancer, and currently lacks effective, standardized treatment options. ReSPECT-LM is designed to explore safe and potentially transformative therapies that could meaningfully improve patient outcomes.
Key Takeaways from SABCS 2025
At SABCS 2025, Dr. Brenner presented Phase 1 dose escalation data highlighting:
- Progress in identifying safe and effective dosing strategies
- Continued advancement of targeted radiotherapeutic approaches for LM
- Ongoing collaboration among leading cancer centers and investigators
These early results represent another important step toward improving care for patients with leptomeningeal metastases.
View the Full Poster Presentation
You can view the complete scientific poster presented at SABCS on the Plus Therapeutics website:
View the poster: https://lnkd.in/daBCCS9F
Learn More About ReSPECT-LM
For detailed trial information, eligibility criteria, and participating sites, visit:
Driving Progress Through Collaboration
Plus Therapeutics is deeply grateful to the clinical investigators, research teams, and trial participants who make this work possible including partners at UT Health San Antonio and the Cancer Prevention and Research Institute of Texas (CPRIT).
Together, these collaborations continue to push forward meaningful innovation for patients with limited treatment options.
About Plus Therapeutics
Plus Therapeutics (NASDAQ: PSTV) is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers, including leptomeningeal metastases and glioblastoma.
#ReSPECTLM #ClinicalTrials #LeptomeningealMetastases #SABCS2025 #BreastCancerResearch #OncologyResearch #NeuroOncology #CancerInnovation #TargetedTherapy #Radiotherapeutics #Phase1Trial #MetastaticBreastCancer #CancerCare #ClinicalResearch #PlusTherapeutics #PSTV #REYOBIQ #CancerTreatment #MedicalResearch #PrecisionMedicine
Recent Comments